NCT04524403 - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

July 29, 2022

Study Completion Date

August 25, 2022

Conditions

Antipsychotic-induced Weight Gain (AIWG)

Interventions

DRUG

Miricorlilant

Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing

DRUG

Miricorlilant

Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing

DRUG

Placebo

Placebo for once-daily oral dosing

Trial Locations (40)

10032

Site #216, New York

10036

Site # 245, New York

10312

Site #231, Staten Island

10314

Site #231, Staten Island

11516

Site # 244, Cedarhurst

19125

Site #166, Philadelphia

19372

Site #235, Thorndale

19380

Site #235, West Chester

27608

Site #181, Raleigh

27610

Site # 181, Raleigh

28211

Site # 248, Charlotte

33016

Site #144, Miami Lakes

33122

Site #202, Miami

33161

Site #144, North Miami

34972

Site #241, Okeechobee

39232

Site #225, Flowood

44720

Site # 230, North Canton

45417

Site #107, Dayton

60640

Site # 240, Chicago

60641

Site #140, Chicago

60712

Site #140, Lincolnwood

63125

Site #224, St Louis

68526

Site #217, Lincoln

72211

Site # 249, Little Rock

72712

Site #143, Bentonville

75080

Site #165, Richardson

75115

Site #206, DeSoto

77030

Site #066, Houston

78754

Site #223, Austin

89102

Site #151, Las Vegas

90230

Site #153, Culver City

90660

Site # 247, Pico Rivera

91206

Site # 243, Glendale

91730

Site # 229, Rancho Cucamonga

91945

Site #134, Lemon Grove

92056

Site #163, Oceanside

92103

Site # 237, San Diego

92845

Site #239, Garden Grove

94305

Site # 150, Stanford

98007

Site #137, Bellevue